Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults

Nat Microbiol. 2022 Feb;7(2):195-199. doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.

Abstract

Here we compared SARS-CoV-2-specific antibody and T-cell responses between older adults (>80 years old, n = 51) and a younger control group (20-53 years old, n = 46) after receiving two doses of BNT162b2. We found that responses in older adults were generally lower, and we identified 10% low-/non-responders. After receiving a third vaccination with BNT162b2, 4 out of 5 low-/non-responders showed antibody and T-cell responses similar to those of responders after two vaccinations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged, 80 and over
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood*
  • BNT162 Vaccine / administration & dosage
  • BNT162 Vaccine / immunology*
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • Humans
  • Immunity, Cellular*
  • Immunity, Humoral*
  • Immunization, Secondary / methods
  • Immunization, Secondary / statistics & numerical data
  • Immunogenicity, Vaccine*
  • Immunoglobulin G / blood
  • Middle Aged
  • Neutralization Tests
  • SARS-CoV-2 / immunology*
  • T-Lymphocytes / immunology
  • Young Adult

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G
  • BNT162 Vaccine